NEW YORK (GenomeWeb) – A prospective, population-based study in Stockholm has shown that a prostate cancer screening method combining plasma protein biomarkers, genetic polymorphisms, and clinical variables may reduce the overdiagnosis that can occur with standard prostate-specific antigen screening.

The study was the result of an ongoing research collaboration between Thermo Fisher Scientific and Henrik Grönberg in Karolinska Institute's department of medical epidemiology and biostatistics.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.